ClinicalTrials.Veeva

Menu
C

Chase Medical Research, LLC | Waterbury, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Retatrutide
Orforglipron
Semaglutide
Bapineuzumab
LY3437943
Insulin icodec
LY3841136
LY3502970

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

39 of 134 total trials

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with anoth...

Enrolling
Lipoprotein(a)
Drug: Enlicitide
Drug: Placebo for enlicitide

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Enrolling
Acute Migraine
Drug: Elismetrep

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Active, not recruiting
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Active, not recruiting
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Active, not recruiting
Hypertension
Drug: Orforglipron
Drug: Placebo

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee oste...

Enrolling
Knee Osteoarthritis (OA)
Obesity
Drug: NNC0487-0111
Drug: Placebo (matched to NNC0487-0111 )

This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive C...

Not yet enrolling
Hypertension
Obesity
Drug: Semaglutide
Drug: Cagrilintide

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)
Locations recently updated

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overwei...

Begins enrollment this month
Overweight
Obesity
Drug: Eloralintide
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide
Locations recently updated

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide...

Enrolling
Overweight
Obesity
Drug: Tirzepatide
Drug: eloralintide and tirzepatide

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Active, not recruiting
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron work...

Active, not recruiting
Osteoarthritis
Drug: Orforglipron
Drug: Placebo

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk o...

Enrolling
Prehypertension
Prediabetic State
Drug: Orforglipron
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide,...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: RO7204239 Matching Placebo

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study...

Enrolling
Type 2 Diabetes Mellitus
Drug: Tifeglipron
Drug: Semaglutide

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with plac...

Enrolling
Migraine
Drug: Placebo
Drug: Elismetrep

Trial sponsors

Lilly logo
Novo Nordisk logo
Pfizer logo
Boehringer Ingelheim logo
Novartis logo
Amgen logo
Bayer logo
Janssen (J&J Innovative Medicine) logo
MannKind logo
Moderna logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems